Diagnosis of Recurrent and Metastatic Disease Using F-18 Fluorodeoxyglucose-Positron Emission Tomography
One of the major strengths of F-18 fluorodeoxyglucose-positron emission tomography (FDG-PET) in breast cancer imaging is in the evaluation of patients who have suspected loco-regional recurrence or distant metastasis. In general, FDG-PET is more sensitive than conventional imaging for the detection of recurrent disease. Because of its ability to more accurately stage patients who have advanced breast cancer, FDG-PET has a significant impact on choice of treatment and management in this patient group.
Department of Radiology, Puget Sound Veterans Administration Health Care System, 1660 South Columbian Way, Seattle, WA 98108-1597, USA
This work was supported in part by National Institutes of Health (NIH) grants RO1CA42045, RO1CA72064, RO1CA90771, and S10RR177229.